CASI Pharmaceuticals Inc (CASI) - Total Assets
Based on the latest financial reports, CASI Pharmaceuticals Inc (CASI) holds total assets worth $24.46 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CASI Pharmaceuticals Inc - Total Assets Trend (1994–2024)
This chart illustrates how CASI Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see CASI stock market capitalisation for the company's overall valuation and market capitalisation.
CASI Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
CASI Pharmaceuticals Inc's total assets of $24.46 Million consist of 73.7% current assets and 26.3% non-current assets. Review CASI Pharmaceuticals Inc total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.1% |
| Accounts Receivable | $15.35 Million | 28.6% |
| Inventory | $5.25 Million | 9.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $238.00K | 0.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1994–2024)
This chart illustrates how CASI Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for CASI Pharmaceuticals Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CASI Pharmaceuticals Inc's current assets represent 73.7% of total assets in 2024, an increase from 25.0% in 1994.
- Cash Position: Cash and equivalents constituted 25.1% of total assets in 2024, up from 25.0% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1994.
- Asset Diversification: The largest asset category is accounts receivable at 28.6% of total assets.
CASI Pharmaceuticals Inc Competitors by Total Assets
Key competitors of CASI Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
CASI Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.30 | 3.20 | 9.28 |
| Quick Ratio | 0.24 | 2.32 | 9.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-27.51 Million | $32.41 Million | $66.05 Million |
CASI Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between CASI Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.65 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -28.7% |
| Total Assets | $53.67 Million |
| Market Capitalization | $4.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values CASI Pharmaceuticals Inc's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: CASI Pharmaceuticals Inc's assets decreased by 28.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CASI Pharmaceuticals Inc (1994–2024)
The table below shows the annual total assets of CASI Pharmaceuticals Inc from 1994 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $53.67 Million | -28.69% |
| 2023-12-31 | $75.27 Million | -21.79% |
| 2022-12-31 | $96.23 Million | -30.42% |
| 2021-12-31 | $138.30 Million | +8.27% |
| 2020-12-31 | $127.73 Million | +24.46% |
| 2019-12-31 | $102.63 Million | -9.50% |
| 2018-12-31 | $113.41 Million | +151.46% |
| 2017-12-31 | $45.10 Million | +62.74% |
| 2016-12-31 | $27.71 Million | +375.65% |
| 2015-12-31 | $5.83 Million | -48.48% |
| 2014-12-31 | $11.31 Million | -27.07% |
| 2013-12-31 | $15.51 Million | +72.73% |
| 2012-12-31 | $8.98 Million | +177.46% |
| 2011-12-31 | $3.24 Million | -59.74% |
| 2010-12-31 | $8.04 Million | -20.16% |
| 2009-12-31 | $10.07 Million | -65.19% |
| 2008-12-31 | $28.92 Million | -45.44% |
| 2007-12-31 | $53.01 Million | -4.85% |
| 2006-12-31 | $55.72 Million | +52.94% |
| 2005-12-31 | $36.43 Million | -7.54% |
| 2004-12-31 | $39.40 Million | -1.87% |
| 2003-12-31 | $40.15 Million | +44.38% |
| 2002-12-31 | $27.81 Million | -39.83% |
| 2001-12-31 | $46.22 Million | +47.14% |
| 2000-12-31 | $31.41 Million | -1.23% |
| 1999-12-31 | $31.80 Million | -19.70% |
| 1998-12-31 | $39.60 Million | -17.15% |
| 1997-12-31 | $47.80 Million | -11.65% |
| 1996-12-31 | $54.10 Million | +435.64% |
| 1995-12-31 | $10.10 Million | +1162.50% |
| 1994-12-31 | $800.00K | -- |
About CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. Th… Read more